Roche Issues Prudent Forecast as Eye Drug’s Sales Disappoint

Roche Holding AG reported disappointing revenue for a blockbuster eye medicine and lackluster growth predictions for the year.

The shares fell in early trading after the Swiss drugmaker said sales of the ophthalmology treatment only rose 7% last quarter amid a slowdown in the US. Roche also issued the same cautious profit and sales forecast as last year, which may prompt some analysts to revise their estimates.